Purpose: Eupatilin is an antioxidative flavone and a phytopharmaceutical derived from Artemisia asiatica. It has been reported to possess anti-tumor activity in some types of cancer including gastric cancer. Eupatilin may modulate the angiogenesis pathway which is part of anti-inflammatory effect demonstrated in gastric mucosal injury models. Here we investigated the anti-tumor effects of eupatilin on gastric cancer cells and elucidated the potential underlying mechanism whereby eupatilin suppresses angiogenesis and tumor growth. Materials and Methods: The impact of eupatilin on the expression of angiogenesis pathway proteins was assessed using western blots in MKN45 cells. Using a chromatin immunoprecipitation assay, we tested whether eupatilin affects the recruitment of signal transducer and activator of transcription 3 (STAT3), aryl hydrocarbon receptor nuclear translocator (ARNT) and hypoxia-inducible factor-1α (HIF-1α) to the human VEGF promoter. To investigate the effect of eupatilin on vasculogenesis, tube formation assays were conducted using human umbilical vein endothelial cells (HUVECs). The effect of eupatilin on tumor suppression in mouse xenografts was assessed. Results: Eupatilin significantly reduced VEGF, ARNT and STAT3 expression prominently under hypoxic conditions. The recruitment of STAT3, ARNT and HIF-1α to the VEGF promoter was inhibited by eupatilin treatment. HUVECs produced much foreshortened and severely broken tubes with eupatilin treatment. In addition, eupatilin effectively reduced tumor growth in a mouse xenograft model. Conclusions: Our results indicate that eupatilin inhibits angiogenesis in gastric cancer cells by blocking STAT3 and VEGF expression, suggesting its therapeutic potential in the treatment of gastric cancer.
Introduction
It has been well demonstrated that neovascularization, or angiogenesis, is required for successful tumor growth and metastasis.
(1) In addition vascular endothelial growth factor (VEGF) is known to be one of the most important and well characterized inducers of angiogenesis. (2) (3) (4) VEGF expression and angiogenesis could be induced as a consequence of microenvironmental alterations, particularly hypoxia, (4) or genetic aberrations, (5, 6) and including the activation of oncogenic kinases. (7, 8) Hypoxia-inducible factor (HIF) is a transcription factor that is stabilized under reduced oxygen tension and plays a key role in the cellular response to hypoxia. HIF is a heterodimer consisting of two subunits, oxygen-sensitive HIF-α and constitutively expressed HIF-β [also known as aryl hydrocarbon receptor nuclear translocator (ARNT), the heterodimeric partner of aryl hydrocarbon receptor (AHR)].(9) Upon hypoxia, HIF-1α heterodimerizes with the constitutively expressed HIF-1β subunit, and together they bind to DNA to increase the transcription of target genes including VEGF, erythropoietin, transferrin, endothelin 1, inducible nitric oxide synthase, and insulin-like growth factor II. (10) (11) (12) Constitutive activation of protein kinases is highly prevalent in a wide range of cancers and their role in VEGF induction and angiogenesis has been well documented. (7, 8) While searching for an antiangiogenic agent that would inhibit HIF-1 activity, we identified a novel pharmacologic activity of eupatilin. Eupatilin, a phytopharmaceutical derived from Artemisia asiatica, has been reported to possess antioxidative and cytoprotective functions in various models of gastric mucosal damage. (18) (19) (20) We found that eupatilin inhibits HIF-1 activity in vitro. Eupatilin completely blocks HIF-1α expression at the post-transcriptional level and consequently inhibits the transcription factor activity of HIF-1 in cancer cells cultured under hypoxic conditions.
In this study, we demonstrated that eupatilin inhibits STAT3 activation in hypoxia-stimulated cancer cells. Further, the transcriptional activation of the VEGF promoter was mediated by active STAT3. Furthermore, active STAT3 interacted with HIF-1 and increased HIF-1 accumulation in the hypoxic cells.
Materials and Methods

Cell culture and hypoxic condition
The human gastric cancer cell line MKN45 was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotics. magnification. All experiments were performed in triplicates. Statistical significance was determined using independent sample twosided Student t-test at the 5% level of significance using SPSS for Windows (version 12.0, SPSS Inc., Chicago, IL, USA). Mice were weighed and tumor measurements were taken in three coordinates using digital calipers two to three times weekly.
Treatment with chemicals
Chromatin immunoprecipitation
Endothelial cell tube formation assay
In vivo tumor model
Tumor measurements were converted to tumor volume using the formula L×S by hypoxia (Fig. 1) . We found that total STAT3 expression was increased by hypoxic conditions. Interestingly, active STAT3, the phosphorylated form, was more significantly reduced with eupatilin treatment in hypoxia than in normoxia. As shown in 2. STAT3 interacts with HIF-1 α and eupatilin inhibits STAT3 recruitment to the VEGF promoter
Our data showed that STAT3 protein expression was greater in hypoxic conditions compared to normoxia, suggesting the important role of STAT3 in regulating VEGF expression in hypoxia ( Fig.   Fig. 1 . Eupatilin inhibits the expression of angiogenesis gene products, HIF-1α, ARNT, STAT3 and VEGF. MKN45 cells were treated with indicated concentration of eupatilin before being cultured for 6 hr under normoxic (20% O 2 v/v) or hypoxic (1% O 2 v/v) conditions. Expression levels of HIF-1α, ARNT, STAT3, phospho-STAT3 were analyzed by immunoblotting. β-actin was used for loading control. Proteins were visualized by enhanced chemiluminescence. HIF-1α = hypoxia-inducible factor-1α; ARNT = aryl hydrocarbon receptor nuclear translocator; STAT3 = signal transducer and activator of transcription 3; VEGF = vascular endothelial growth factor.
1). We thus hypothesized that VEGF expression is cooperatively regulated by HIF-1α and ARNT, as well as by STAT3. To test this hypothesis, we first investigated possible interaction between
HIF-1α, STAT3, ARNT and VEGF using the co-immunoprecipitation assays. MKN45 cells grown under either normoxic or hypoxic conditions were lysed and immunoprecipitated with an anti-HIF-1α antibody, followed by Western blotting with anti-STAT3, ARNT, or VEGF antibodies. We found that STAT3 and VEGF were co-precipitated with HIF-1α in normoxic or hypoxic cells ( Fig. 2A) . Interestingly, for reasons yet to be explained, ARNT was co-precipitated with HIF-1α only in hypoxic conditions.
To investigate whether STAT3, HIF-1α, and ARNT might be recruited to the VEGF promoter and whether eupatilin may be inhibiting the interaction between the angiogenic proteins and the VEGF promoter, we performed ChIP assays on chromatin samples from normoxic and hypoxic cells with eupatilin treatment. As expected, a slight increased in the interaction of HIF-1α with the VEGF promoter was observed for hypoxia (Fig. 2B ).
Eupatilin directly decreases HUVEC capillary tube formation
In light of the role of eupatilin in suppressing the angiogenic pathway as suggested above, we next investigated the effect of eupatilin on vascular endothelial cells under hypoxic conditions. In vitro angiogenesis assays were conducted using HUVECs. During angiogenesis, endothelial cells must break and traverse through their basement membrane to form new blood vessels. Hypoxia can stimulate endothelial cell invasion and tube formation. Eupatilin was administered to HUVECs seeded on Matrigel beds (10 mg/ ml) and incubated for 16 hr under hypoxic conditions. Eupatilin strongly inhibited the hypoxia-stimulated capillary network formation. With increasing doses of eupatilin, vasculogenesis was significantly inhibited as evidenced by the production of considerably foreshortened and severely broken tubes (Fig. 3) . Tumors in eupatilin-treated mice were significantly smaller than those in vehicle-treated mice (Fig. 4A) . The changes in tumor size was measured and plotted as average tumor size versus time (data not shown). When ex vivo tumor weight was measured upon sacrifice, there was a significant difference in tumor weight between the control (vehicle only) and EPT groups (Fig 4B) . These results indicated that eupatilin effectively inhibited tumor growth in a xenograft tumor model.
Discussion
Angiogenesis is essential for the growth and metastasis of solid tumors, and the inhibition of angiogenesis is emerging as a promising strategy for cancer treatment. (21) to the VEGF promoter was observed in the hypoxia as expected (Fig. 2B) . However, for reasons yet to be determined, the binding 
